Defining the null hypothesis
Virus B is a newly emerged viral strain for which there is no current treatment. Drug A was identified as a potential treatment for infection with virus B. In this pre-clinical phase of drug testing, the effects of drug A on survival after infection with virus B was tested. There was no difference i...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552992/ |
| id |
pubmed-4552992 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-45529922015-08-30 Defining the null hypothesis Saxon, Emma Comment Virus B is a newly emerged viral strain for which there is no current treatment. Drug A was identified as a potential treatment for infection with virus B. In this pre-clinical phase of drug testing, the effects of drug A on survival after infection with virus B was tested. There was no difference in survival between control (dark blue) and drug A-treated, virus B-infected mice (green), but a significant difference in survival between control and virus B-infected mice without drug treatment (light blue, z-test for proportions P < 0.05, n = 30 in each group). The authors therefore concluded that drug A is effective in reducing mouse mortality due to virus B. BioMed Central 2015-08-29 /pmc/articles/PMC4552992/ /pubmed/26319022 http://dx.doi.org/10.1186/s12915-015-0181-x Text en © Saxon. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Saxon, Emma |
| spellingShingle |
Saxon, Emma Defining the null hypothesis |
| author_facet |
Saxon, Emma |
| author_sort |
Saxon, Emma |
| title |
Defining the null hypothesis |
| title_short |
Defining the null hypothesis |
| title_full |
Defining the null hypothesis |
| title_fullStr |
Defining the null hypothesis |
| title_full_unstemmed |
Defining the null hypothesis |
| title_sort |
defining the null hypothesis |
| description |
Virus B is a newly emerged viral strain for which there is no current treatment. Drug A was identified as a potential treatment for infection with virus B. In this pre-clinical phase of drug testing, the effects of drug A on survival after infection with virus B was tested. There was no difference in survival between control (dark blue) and drug A-treated, virus B-infected mice (green), but a significant difference in survival between control and virus B-infected mice without drug treatment (light blue, z-test for proportions P < 0.05, n = 30 in each group). The authors therefore concluded that drug A is effective in reducing mouse mortality due to virus B. |
| publisher |
BioMed Central |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552992/ |
| _version_ |
1613470294472654848 |